



**Regarding the Adoption of Public Offering for “the Project that Establish Biopharmaceutical Manufacturing Bases to Strengthen Vaccine Production Structure” Led by the Ministry of Economy, Trade and Industry  
- Establishing domestic vaccine manufacturing for future pandemics -**

**OSAKA, Japan, September 21, 2023** - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi Pharma Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Akira Kato; hereafter "Shionogi Pharma") was established by the Ministry of Economy, Trade and Industry has included us as a company of the public offering for the project of biopharmaceutical manufacturing bases to strengthen vaccine production structure (hereafter "this project"). Shionogi Pharma was adopted for "Development of formulation/filling bases" of this project.

Shionogi and its subsidiaries Shionogi Pharma and UMN Pharma have been pursuing the development of a recombinant protein vaccine using a unique technology BEVS\*, and have been establishing the vaccine manufacturing structure, including scale-up for commercial use. We will use the subsidy from this project to construct a new vaccine formulation plants on the premises of Shionogi Pharma's Settsu Plant, thereby strengthening its production capabilities and building further preparations for future crises.

\* Baculovirus Expression Vector System: Protein expression technology using insect cell-derived

Shionogi is committed to the principle "Protecting people worldwide from the threat of infectious diseases" as our key focus, working toward total care for infectious diseases. We will be continuing to promote initiatives to work R&D of infectious disease area and production structure so it will be ready in times so that we can quickly provide vaccines and drugs in preparation for future pandemics.

[Summary of adoption]

Subject of development subsidy	Development of formulation/filling bases
Companies receiving subsidies	Shionogi Pharma Co., Ltd.
Place of the project	Settsu City, Osaka (Shionogi Pharma Settsu Plant)
Adoption date	September 20, 2023

## References

1. About "Biopharmaceutical Manufacturing Base Development Project of Strengthen Vaccine Manufacturing" (second public solicitation)  
<https://www.meti.go.jp/information/publicoffer/kobo/2023/k230317001.html> (Only Japanese)

## ■ About Shionogi Pharma Co., Ltd.

Shionogi Pharma, which is responsible for the production-related functions of the SHIONOGI Group, started operations on April 1, 2019 with the mission of becoming a "technology development-oriented manufacturing company" that provides new manufacturing methods and products globally. We have established a system that allows us to provide a full range of services, including development of manufacturing methods for active pharmaceutical ingredients, development of formulations, and commercial production, as well as

development of analytical methods and equipment design support using pharmaceutical engineering technology. For more information, please visit: <https://www.shionogi-ph.co.jp/en/>

■ **UMN Pharma Inc.**

UMN Pharma has Protein expression technology using insect cell-derived, since March 2020, we have been a member of the SHIONOGI Group and are responsible for the development and manufacture of manufacturing methods for the active pharmaceutical ingredients of infectious disease prevention vaccines. For more information, please visit: <https://www.umnpharma.com/en/>

**Forward-Looking Statements**

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

**For Further Information, Contact:**

SHIONOGI Website Inquiry Form : <https://www.shionogi.com/global/en/contact.html>